UK Has Sought Advice On Compulsory Licensing For Vertex’ Orkambi
Pressure on Vertex over access to its cystic fibrosis drug Orkambi in England is mounting after the parliamentary undersecretary for health admitted the government has already taken advice on compulsory licensing of the product.
You may also be interested in...
The UK’s main opposition party says it would use compulsory licensing to ensure access to “extortionately” priced medicines. Unsurprisingly, the responses are polarized.
The UK government will consider all options to improve access to Vertex’s cystic fibrosis treatment, including compulsory licensing.
Vertex and bioindustry groups have called on a UK inquiry investigating the availability of the cystic fibrosis drug Orkambi on the National Health Service not to publish confidential information.